Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study

被引：3

作者：

Sun, Pengfei ^{[1
]}

Zhang, Ying ^{[2
]}

Tian, Shilin ^{[3
]}

Cui, Kai ^{[1
]}

Zhong, Jingtao ^{[1
]}

Zhang, Chengsheng ^{[1
]}

Wang, Dongxu ^{[4
]}

Zhang, Bo ^{[1
]}

Shi, Xuetao ^{[1
]}

Li, Zhongchao ^{[1
]}

机构：

[1] Shandong First Med Univ, Dept Hepatobiliary Surg, Shandong Canc Hosp, Huaiyin Dist, Jinan, Peoples R China

[2] Peoples Hosp Shizhong Dist, Dept Nephrol, Jinan, Peoples R China

[3] Shandong First Med Univ, Dept Intervent Oncol, Shandong Canc Hosp, Jinan, Peoples R China

[4] Shandong Univ, Dept Hepatobiliary Surg, Qilu Hosp, Jinan, Peoples R China

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2024年 / 20卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Combination therapy; hepatocellular carcinoma; PD-1; inhibitor; regorafenib; 2ND-LINE THERAPY; DOUBLE-BLIND; CHEMOEMBOLIZATION; ABLATION;

D O I：

10.4103/jcrt.jcrt_2376_23

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Backgrounds:Programmed death receptor 1 (PD-1) monoclonal antibody has been approved for the first and second-line treatments of hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of tislelizumab + regorafenib as a second-line treatment option for advanced HCC.Methods:Treatment-related adverse events (TRAEs) were the primary endpoints in this clinical trial comprising 28 patients with advanced HCC. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).Results:According to the mRECIST 1.1 evaluation criteria, the ORR was 28.6%. Complete and partial response were observed in 3 and 5 patients, respectively; stable disease was observed in 12 patients (DCR, 71.4%). The median PFS was 6.4 months. The incidence of grade 1-2 and 3-4 TRAEs was 57.1% and 39.3%, respectively.Conclusion:This study suggests that tislelizumab + regorafenib can be used as a second-line treatment for advanced HCC.

引用

页码：1344 / 1349

页数：6

共 27 条

[1]

[Anonymous], Nano-immunotherapy:Unique mechanisms of nanomaterials in synergizing cancer immunotherapy |Semantic Scholar

[2] Burden of liver diseases in the world [J].

Asrani, Sumeet K. ;

Devarbhavi, Harshad ;

Eaton, John ;

Kamath, Patrick S. .

JOURNAL OF HEPATOLOGY, 2019, 70 (01) :151-171

[3] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[4] Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice [J].

Chen, Yu ;

Pei, Yanqing ;

Luo, Jingyu ;

Huang, Zhaoqin ;

Yu, Jinming ;

Meng, Xiangjiao .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[5] Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib [J].

Erdogan, Bulent ;

Ozcan, Erkan ;

Gokmen, Ivo ;

Gokyer, Ali ;

Kucukarda, Ahmet ;

Kostek, Osman ;

Hacioglu, Muhammet Bekir ;

Uzunoglu, Sernaz ;

Cicin, Irfan .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (03) :762-767

[6] Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J].

Finn, Richard S. ;

Ryoo, Baek-Yeol ;

Merle, Philippe ;

Kudo, Masatoshi ;

Bouattour, Mohamed ;

Lim, Ho Yeong ;

Breder, Valeriy ;

Edeline, Julien ;

Chao, Yee ;

Ogasawara, Sadahisa ;

Yau, Thomas ;

Garrido, Marcelo ;

Chan, Stephen L. ;

Knox, Jennifer ;

Daniele, Bruno ;

Ebbinghaus, Scot W. ;

Chen, Erluo ;

Siegel, Abby B. ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :193-+

[7] Regorafenib and trifluridine/tipiracil in real clinical practice [J].

Garcia-Beloso, Nerea ;

Yaiza Romero-Ventosa, Elena ;

Gayoso-Rey, Monica ;

Lopez-Lopez, Aida ;

Robles-Torres, David ;

Martinez-Lopez de Castro, Noemi ;

Pineiro-Corrales, Guadalupe .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (09) :S367-S373

[8] Experience with regorafenib in the treatment of hepatocellular carcinoma [J].

Granito, Alessandro ;

Forgione, Antonella ;

Marinelli, Sara ;

Renzulli, Matteo ;

Ielasi, Luca ;

Sansone, Vito ;

Benevento, Francesca ;

Piscaglia, Fabio ;

Tovoli, Francesco .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14

[9] Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study [J].

Li, Tao ;

Zhao, Jingfang ;

Zhang, Shuai ;

Wang, Hui ;

Sun, Linlin ;

Hu, Jinhua .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (01) :57-63

[10] Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment [J].

Lisi, Lucia ;

Lacal, Pedro Miguel ;

Martire, Maria ;

Navarra, Pierluigi ;

Graziani, Grazia .

PHARMACOLOGICAL RESEARCH, 2022, 175

← 1 2 3 →